Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AK Clear all
Recruiting Early Phase 1 Interventional

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients

NCT07286318
View directory record Official record
Conditions
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Actinic Keratosis (AK), Organ Transplant Recipient
Interventions
Topical niacinamide 5% cream, Sunscreen
Drug
Lead sponsor
Marissa Lobl
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 21, 2026, 2:43 PM EDT
Completed No phase listed Observational

A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study

NCT00989313
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Lesion count
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Hot Springs, Arizona • San Diego, California • Alpharetta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 1 Interventional

Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp

NCT01836367
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol Mebutate 0.015%
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

NCT00021294
View directory record Official record
Conditions
Non-melanomatous Skin Cancer, Precancerous/Nonmalignant Condition
Interventions
eflornithine, triamcinolone
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 21, 2026, 2:43 PM EDT
Terminated Phase 2 Interventional

ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients

NCT00865878
View directory record Official record
Conditions
Actinic Keratoses, Skin Neoplasms
Interventions
Aminolevulinic Acid, Vehicle
Drug · Other
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Irvine, California • San Francisco, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2011 · Synced Oct 21, 2026, 2:43 PM EDT
Recruiting Phase 3 Interventional

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities

NCT07144852
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E.
Drug · Other · Device
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Phoenix, Arizona • Fremont, California • Castle Rock, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)

NCT04319159
View directory record Official record
Conditions
Actinic Keratoses
Interventions
BF-200 ALA and red light LED lamp
Combination Product
Lead sponsor
Biofrontera Bioscience GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 21, 2026, 2:43 PM EDT
Withdrawn Phase 3 Interventional

Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp

NCT03024060
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ALA, Vehicle, IBL 20 mW, IBL 10 mW
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
San Diego, California • Arlington Heights, Illinois • Carmel, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 21, 2026, 2:43 PM EDT
Not listed Phase 4 Interventional

Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses

NCT01229319
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
Drug
Lead sponsor
Frankel, Amylynne, M.D.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream

NCT03727074
View directory record Official record
Conditions
Actinic Keratosis (AK)
Interventions
5-FU Cream, Efudex®, Vehicle
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cerritos, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 21, 2026, 2:43 PM EDT
Withdrawn Not applicable Interventional

Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses

NCT00814528
View directory record Official record
Conditions
Actinic Keratosis
Interventions
5-ALA plus Blu-Light, 5-FU, Imiquimod or treatment with cryotherapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 21, 2026, 2:43 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Qungasvik (Toolbox)-Healthy Hearts: A Cultural Approach to Reducing Chronic Disease Risk

NCT07829341
View directory record Official record
Conditions
Cardio Vascular Disease, Cerebro Vascular Disease, Mental Health, Chronic Disease (Physical)
Interventions
Qungasvik-Healthy Hearts
Behavioral
Lead sponsor
University of Alaska Fairbanks
Other
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Fairbanks, Alaska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Not applicable Interventional

Gambro AK200 ULTRA Hemodiafiltration Study

NCT01202708
View directory record Official record
Conditions
Chronic Renal Failure
Interventions
On line hemofiafiltration, On line hemodiafiltration
Device
Lead sponsor
Vantive Health LLC
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 21, 2026, 2:43 PM EDT
Completed No phase listed Observational Results available

Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis

NCT05260073
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Tirbanibulin
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses

NCT02251652
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Ingenol Mebutate, Cryotherapy
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream

NCT00335179
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Aldara (imiquimod 5% cream), Vehicle cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2010 · Synced Oct 21, 2026, 2:43 PM EDT
Recruiting No phase listed Observational

AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring

NCT07210021
View directory record Official record
Conditions
Hyperkalemia, Chronic Kidney Disease (Stage 3-4)
Interventions
AK+ Guard™ ECG Application
Device
Lead sponsor
AccurKardia, Inc.
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 1 Interventional

Treatment of Actinic Keratoses (AK) on the Face

NCT02411851
View directory record Official record
Conditions
Actinic Keratoses
Interventions
ingenol mebutate 0.015%, dermasil lotion
Drug · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands

NCT00115154
View directory record Official record
Conditions
Keratosis
Interventions
Aldara (imiquimod) cream, 5%
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
18
States / cities
Tucson, Arizona • Vista, California • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2007 · Synced Oct 21, 2026, 2:43 PM EDT
Not listed Not applicable Interventional

NdYag Laser for Acne Keloidalis Nuchae

NCT00757315
View directory record Official record
Conditions
Acne Keloidalis Nuchae, NdYag Laser, AKN, Acne Keloidalis, AK, Dermatitis Papillaris Capillitii, Folliculitis Keloidalis Nuchae, Sycosis Nuchae, Acne Keloid, Keloidal Folliculitis, Lichen Keloidalis Nuchae, Folliculitis Nuchae Scleroticans, Sycosis Framboesiformis
Interventions
NdYag Laser(hair removal laser) plus topical corticosteroid, Topical corticosteroid alone
Device · Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)

NCT01458587
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Aminolevulinic Acid PDT (ALA), Vehicle PDT (VEH)
Drug
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
San Diego, California • Orange Park, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 21, 2026, 2:43 PM EDT
Recruiting No phase listed Observational

Outcomes Associated With Tirbanibulin for Large Field Application on the Face in the U.S (CLEAR)

NCT07657988
View directory record Official record
Conditions
Actinic Keratosis (AK)
Interventions
Tirbanibulin
Drug
Lead sponsor
Avant Health LLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Manhattan Beach, California • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis

NCT01516515
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Vehicle gel, SR-T100 with 2.3% of SM
Drug
Lead sponsor
G&E Herbal Biotechnology Co., LTD
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
8
States / cities
Rancho Mirage, California • Longmont, Colorado • West Palm Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 3 Interventional

Protocols for Painless Photodynamic Therapy (PDT) of Actinic Keratoses

NCT02124733
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Aminolevulinic acid based photodynamic therapy
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 21, 2026, 2:43 PM EDT